ABNX.PA ABIONYX EURONEXT +24.00% to €3.72 pre-market 28 Mar 2026: high vol

ABNX.PA stock surged 24.00% in pre-market trading on EURONEXT to €3.72 on 28 Mar 2026. The move followed heavy activity with 1,373,168.00 shares trading versus an average of 131,653.00. The gap higher opened from €3.25 to €3.72, driven by volume and renewed interest in ABIONYX Pharma SA’s pipeline and sector momentum. We use Meyka AI’s real-time tools and data to explain what moved the price, the valuation context, and what traders should watch next on EUR, volume, and catalyst flow

ABNX.PA stock pre-market move and volume

ABNX.PA stock jumped 24.00% to €3.72 in pre-market on EURONEXT with volume at 1,373,168.00. The intraday range shows a low of €3.21 and a high of €3.90. This is a clear short-term demand surge compared with the 50-day average €3.54 and 200-day average €3.10. Institutional follow-through or newsflow can sustain the move given the relative volume of 10.43x the average

Why ABNX.PA stock jumped: company and sector context

ABIONYX Pharma SA (ABNX.PA) develops therapies for renal and ophthalmological diseases and is listed on EURONEXT in Europe. The move ties to pipeline attention around CER candidates and sector rotation into healthcare. The Healthcare sector shows modest weakness year-to-date, but biotech names trade on binary clinical and partnership news. ABIONYX’s year high is €5.29 and year low is €1.09, leaving room for headline-driven swings

Fundamentals and valuation for ABNX.PA stock

ABNX.PA reports EPS -0.13 and a negative P/E of -28.58, reflecting current losses. Price-to-sales is 32.23 and price-to-book is 31.50, signalling a valuation premium versus typical biotech peers. Market cap stands at €130,982,623.00 and shares outstanding are 35,257,772.00. Current ratio is 1.06 and debt-to-equity is 0.89, showing limited liquidity buffer and meaningful leverage for its size

Technical view and trading signals for ABNX.PA stock

Technicals show momentum but mixed risk. RSI is 63.34, MACD histogram ticked positive, and ADX at 33.38 indicates a strong short-term trend. Bollinger upper band sits at €3.57, middle at €3.28, supporting the breakout. Watch ATR €0.21 for stop placement and daily range. Overbought CCI at 195.57 warns of a pullback risk after the pre-market gap

Meyka AI rates ABNX.PA with a score out of 100 and forecast

Meyka AI rates ABNX.PA with a score out of 100: 65.03 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €3.17, quarterly €4.42, and yearly €5.87. Versus the current €3.72, the quarterly projection implies 18.82% upside and the yearly implies 57.80% upside. Forecasts are model-based projections and not guarantees

Risks, catalysts and trading strategy for ABNX.PA stock

Key risks include further cash burn, negative EPS, and binary trial or partnership outcomes that can swing price quickly. Catalysts to watch are regulatory updates, partnership announcements, and the next earnings date on 2026-09-24. For traders, consider scaled entries, a stop near the lower daily band, and position size aligned with biotech volatility. Investors should weigh long-term pipeline milestones against weak profitability metrics

Final Thoughts

ABNX.PA stock is the top pre-market gainer on EURONEXT after a 24.00% jump to €3.72 on 28 Mar 2026. The raw signals are clear: heavy volume at 1,373,168.00, trend strength with ADX 33.38, and momentum-driven price action. Fundamentals remain challenging, with EPS -0.13, negative P/E -28.58, and elevated price-to-sales 32.23, so any upside will likely need clinical or partnership validation. Meyka AI’s model shows a near-term quarterly target of €4.42 (+18.82%) and a 12-month target of €5.87 (+57.80%) versus the current €3.72. These forecasts are model-based projections and not guarantees. Traders should monitor volume, upcoming company updates, and sector flows. For deeper data and live signals, see our Meyka AI stock page and the MarketWatch company profile for primary filings and background Meyka ABNX page MarketWatch profile. Remember, Meyka AI provides data-driven market analysis but not investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.